Navigation Links
Cannabis Science In Final Negotiations To Establish Its First Medical Cannabis Facilities In Canada

COLORADO SPRINGS, Colo., Aug. 7, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB:CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture company for the purpose of acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada.

The Company believes that this joint venture has the potential to expand the Company's operations outside of the United States and to allow the Company's entry and expansion into Canada's marketplace.

"Acquiring cannabis facilities in Canada represents a compelling business opportunity developed through our focus on collaborative innovation and takes one of our international initiatives to the next level," said Chad S. Johnson, Director, COO and General Counsel of the Company. "We are excited to be working jointly with our partners, which allows us to leverage our respective global research knowledge and resources to facilitate the Canadian operations. The Company also intends to use these facilities for research and development purposes in addition to the selling of the cannabis products under relevant laws and regulations.  More to come."

While the Company is optimistic about the potential for commercialization of cannabis products, it recognizes that, as with the acquisition and development cannabis facilities, the process can be lengthy and without assurances.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected.  A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future events or future performance, but reflect CBIS management's current beliefs, based on information currently available. Some or all of the events or results anticipated by these forward-looking statements may not occur. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements.

Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements, whether as a result of new information, future events or otherwise.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
Tel: 1.561.420.4824

Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
Tel: 1.310.650.3788

SOURCE Cannabis Science, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Develops a Cannabis-based Epilepsy Medication
2. Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
3. Technology Driving Cannabis Industry
4. CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial Officer, Robert Kane
5. Medbox Executes Consulting Agreement with Licensed Medical Cannabis Laboratory and Cultivation Center in Canada
6. Cannabis Science (CBIS) Moves Forward with Critical Support of Landmark Federal Cannabis Legislative Initiative
7. GrowLife Debuts First Kiosk-Based Payment, Cash Management, and Regulatory Compliance Technology for Legal Cannabis Dispensaries
8. Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
9. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
10. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
11. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
(Date:11/25/2015)... ... ... SCOTTSDALE, AZ) - Today, Dr. Todd C. Hobgood ... non-surgical treatments, announced the expansion of his private practice capabilities with the grand ... trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
Breaking Medicine News(10 mins):